| Study | Arm Dose mg/Day (N) | Duration (Weeks) | Population Trauma Type | Baseline PTSD Severitya | Mean Age (Y) | % Female | % Non-white | Risk of Bias |
|---|---|---|---|---|---|---|---|---|
| Davidson et al., 200669 | Total 538b Venlafaxine 37.5 to 375 mg (179) Sertraline 25 to 200 mg (173) Placebo (179) | 12 | Male and female Mixed | ~82 | NR | NR | NR | Medium |
| Petrakis et al., 2012185 | Paroxetine 40 mg + Naltrexone 50 mg (22) (arm not eligible) Paroxetine 40 mg + Placebo (20) Desipramine 200 mg + Naltrexone 5 Placebo 0 mg (22) (arm not eligible) Desipramine 200 mg + (24) | 12 | Male and female Veterans w/alcohol dependence | 62.5 to 77.8 | 47 | 9 | 25 | Medium |
| Sonne et al., 2016186 | Sertraline 25 to 200 mg (109) Venlafaxine 37.5 to 375 mg (98) | 24-28 | Trauma, affected refugees, Catastrophic experience Unknown what portion of the sample had clinical PTSD | HTQ 3.18 to 3.24 | 44 | 40 | NR | Medium |
| Tucker et al., 2003175 Tucker et al., 2004176 | Citalopram 20 to 50 mg (25) Sertraline 50 to 200 mg (23) Placebo (10) | 10 | Male and female Mixed | 83.9 to 94.2 | 39 | 74 | 14 | Medium |
Data reported are mean CAPS or range of mean CAPS scores across groups unless otherwise specified.
The Ns for each are the number analyzed; the number randomized to each group was not reported (overall N was 538; 531 were included in the analysis).
CAPS = Clinician-Administered PTSD Scale; F = female; mg = milligram; HTQ = Harvard Trauma Questionnaire; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = years.
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.